Updates in EGFRm NSCLC at WCLC 2025: FLAURA2, ACROSS 2 & HARMONi
Автор: VJOncology
Загружено: 2025-09-08
Просмотров: 340
Описание:
Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, discusses recent developments in EGFR-mutated non-small cell lung cancer (NSCLC). The FLAURA2 trial (NCT04035486) demonstrated a significantly improved overall survival in patients receiving first-line osimertinib and chemotherapy over osimertinib alone. The Phase III ACROSS 2 trial (NCT04500717) showed that aumolertinib with chemotherapy showed a promising progression-free survival (PFS), and the HARMONi trial (NCT05499390) demonstrated that ivonescimab with chemotherapy significantly increased PFS in pretreated patients. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
